Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Expert Rev Anticancer Ther. 2018 Jul 17;18(9):837–860. doi: 10.1080/14737140.2018.1496822

Table 5:

Recent results (2013–2017) with 68Ga-DOTA-SSA PET/CT : Sensitivity, specificity with panNETs only and all NETs (Part A); comparison with 111In-Penetreotide SPECT/CT (Part B) and prognostic value for tumor grade/differentiation or survival (Part C).

A. Recent results 68Ga-DOTA-SSA PET/CT: Sensitivity, specificity with panNETs only and all NETs

  1. Sensitivity with panNETs only : 2017[(95%)[282],(88%)[283],; 2016[(92)[126],(88%); 2014[(84%)[284],(98%)[285], (100%)[123]; 2013[(100%)[286],(68%)[125]

  2. Sensitivity with series containing various GI-NETs including panNETs: 2017[(82%)[113],(92%)[126], (92%)[19]; 2016[(99.9%)[287],(96%)[288],(97%)[120], (95%)[289], (100%)[141]; 2015[(100%)[290]; 2014[(94%)[291],(95%)[24],(91%)[136],(96%)[123]; 2013[(98%)[292],(86%)[111]

  3. Specificity with panNETs only: 2017[(100%)[126]; 2016[(83%)[126]; 2014[(100) [123]

  4. Specificity with series containing various GI-NETs including panNETs: 2017[(100%)[113],(88%)[19]; 2016[(93%)[288],(97%)[120]; 2014[(95%)[291],(50%)[136], (97%)[123]; 2013[(100%)[292]

B. Recent results 68Ga-DOTA-SSA PET/CT: Compared to 111In-Penetreotide SPECT/CT

  1. Sensitivity with series containing various GI-NETs including panNETs: 2017[(100% vs 78%) [14], 2016[(99.9% vs 60%)[287],(96% vs 72%)[288], (95% vs 45%)[289]; 2015[(100% vs 54%)[290]

  2. Specificity with series containing various GI-NETs including panNETs: 2016[(93% vs 93%)[288]

C. Recent results 68Ga-DOTA-SSA PET/CT: ability of the addition of 68Ga-DOTA-SSA PET/CT to change patient management (% of patients)

  1. 2017 (50%) [131], (51%) [14], (39%) [85], (73%) [122], (50%) [143]; 2016 (36%) [288], (40%) [120],(33%) [289]; 2014 (75%) [121]; 2013 (59%) [292],(17%) [111]

D. 68Ga-DOTA-SSA PET/CT findings correlating with prognosis: grade/differentiation/survival

  1. 68Ga-DOTA-SSA PET/CT has high sensitivity for detection of metastatic disease both in lymph nodes and liver, as well as distant metastases (bone, etc.), all of which have a major impact on treatment, prognosis and survival [1,5,7,10,94,122,124,292]

  2. Determination of 68Ga-DOTA-SSA PET/CT-avid tumor volume (TV) inversely correlated with PFS(p=0.001) and overall disease related survival(OS)(P=0.002)[293].

  3. In various studies [111,137,143,294,295] 68Ga-DOTA-SSA PET/CT’s tumor standardized uptake value(SUV) correlate with PFS, Ki-67, tumor grade/differentiation or tumor progression, whereas in others [114,283]no correlation with Ki-67, grade or sst receptor density

  4. The degree of 68Ga-DOTA-SSA PET/CT uptake by the NET correlates with sst2 expression determine by immunohistochemistry which was an independent predictor of OS (p=0.037)[28]

E. 68Ga-DOTA-SSA PET/CT findings correlating with response to PRRT

  1. 68Ga-DOTA-SSA PET/CT SUV correlated with the degree of uptake of radioligand on PRRT [134] and a SUV/max cutoff of 16.4 was predictive of responding lesions with sensitivity of 95% and specificity of 60%[135]